BioSpace News Archive

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-authorized Nerivio® prescribed wearable for the acute treatment of migraine is now eligible for insurance coverage through the UpScript direct-to-patient telemedicine platform.

The launch of Medidata Risk Management, coupled with updates to Medidata Detect, round out a full suite of unified RBQM solutions, built on the Medidata Clinical CloudTM

Overall, the 3rd PRO found similar or comparable efficacy and yield results evaluating MustGrow’s natural mustard-derived biological products versus the widely-used synthetic fumigation chemical, Chloropicrin.

Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team as of April 1st, 2021.

Kathy Giusti, MBA, Founder and Chief Mission Officer of the Multiple Myeloma Research Foundation and Co-Chair the Harvard Business School Kraft Precision Medicine Accelerator; Nancy P. Pelosi, Speaker of the U.S. House of Representatives; and Charles L. Sawyers, MD, FAACR, world-renowned cancer researcher and AACR Past President, received their awards virtually at the AACR Annual Meeting 2021 on April 11, 2021.

OpRegen ® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD

Shapa Health Inc. has appointed Dr. Adi Leiba as its Chief Medical Officer

VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) VBI-2601 (BRII-179) was well-tolerated with no safety signals observed at both low- and high-dose levels

Two poster presentations will feature analyses from the clinical development program that further characterize the efficacy and safety profile of WAKIX

Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will exercise its option to purchase all rights to a G-coupled protein receptor (GPCR) library and its proprietary Twist Antibody Optimization (TAO) software, both developed in collaboration with Distributed Bio.